The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH

Angelo Iacobino; Federico Giannoni; Manuela Pardini; Giovanni Piccaro; Lanfranco Fattorini

doi:10.1128/AAC.00273-19

The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH

Angelo Iacobino, Federico Giannoni, Manuela Pardini, Giovanni Piccaro, Lanfranco Fattorini

Istituto Superiore di Sanita'

Research output: Contribution to journal › Article › peer-review

Abstract

The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.

Original language	English
Article number	e00273-19
Journal	Antimicrobial Agents and Chemotherapy
Volume	63
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00273-19
Publication status	Published - 2019

Keywords

Hypoxia
Mycobacterium tuberculosis
Nitazoxanide
PH
Rifampin
Tuberculosis

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00273-19

Fingerprint Dive into the research topics of 'The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH'. Together they form a unique fingerprint.

Cite this

The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH. / Iacobino, Angelo; Giannoni, Federico; Pardini, Manuela; Piccaro, Giovanni; Fattorini, Lanfranco.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 7, e00273-19, 2019.

Research output: Contribution to journal › Article › peer-review

@article{2beb6b341a654389a9a5b5abfceff7e7,

title = "The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH",

abstract = "The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.",

keywords = "Hypoxia, Mycobacterium tuberculosis, Nitazoxanide, PH, Rifampin, Tuberculosis",

author = "Angelo Iacobino and Federico Giannoni and Manuela Pardini and Giovanni Piccaro and Lanfranco Fattorini",

year = "2019",

doi = "10.1128/AAC.00273-19",

language = "English",

volume = "63",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH

AU - Iacobino, Angelo

AU - Giannoni, Federico

AU - Pardini, Manuela

AU - Piccaro, Giovanni

AU - Fattorini, Lanfranco

PY - 2019

Y1 - 2019

N2 - The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.

AB - The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.

KW - Hypoxia

KW - Mycobacterium tuberculosis

KW - Nitazoxanide

KW - PH

KW - Rifampin

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85068107595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068107595&partnerID=8YFLogxK

U2 - 10.1128/AAC.00273-19

DO - 10.1128/AAC.00273-19

M3 - Article

C2 - 31010861

AN - SCOPUS:85068107595

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

M1 - e00273-19

ER -